Investors & Media

Transformative science, targeted medicines

We are working to advanceĀ a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

SEC filing details

Document Details

Filing Date
Apr 21, 2021
Document Date
Apr 21, 2021
Form Description
Additional proxy soliciting materials - definitive
Filing Group
Proxy Filings
Company
Blueprint Medicines Corp.
Issuer
Blueprint Medicines Corp